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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: In this narrative review of the current literature, we examine the traditional risk 
factors and patient proﬁ  les leading to cardiovascular disease and osteoporosis. We discuss 
the interrelationships between risk factors and common pathophysiological mechanisms for 
cardiovascular disease and osteoporosis. We evaluate the increasing evidence that supports an 
association between these disabling conditions. We reveal that vascular health appears to have 
a strong effect on skeletal health, and vice versa. We highlight the importance of addressing 
the risk beneﬁ  t of preventative interventions in both conditions. We discuss how both sexes are 
affected by these chronic conditions and the importance of considering the unique risk of the 
individual. We show that habitual physical activity is an effective primary and secondary pre-
ventative strategy for both cardiovascular disease and osteoporosis. We highlight how a holistic 
approach to the prevention and treatment of these chronic conditions is likely warranted.
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Introduction
Cardiovascular disease (CVD) and osteoporosis (ie, reduced bone mass and microar-
chitectural deterioration of bone) are major health problems in North America, whose 
incidence increases with advancing age (Warburton et al 2006a). The socioeconomic 
and health care burden of osteoporosis and CVD on society is enormous (Johnell 
1997). Osteoporotic fractures (Braithwaite et al 2003) and CVD-related events are key 
origins of morbidity and premature mortality in the elderly (Warburton et al 2006a). 
Moreover, post-menopausal women appear to be particularly at risk for developing 
both osteoporosis and CVD. In fact, once a woman reaches menopause, the risk for 
both osteoporosis and CVD increases substantially. Moreover, CVD and osteoporosis 
are often observed in the same individual (Schulz et al 2004).
Globally, CVD is a major cause of premature mortality accounting for approxi-
mately one-third of the cases of death. According to the World Health Organization 
approximately 17 million people die as a result of CVD each year (World Health 
Organization 2006).
In the United States, approximately 10 million individuals have osteoporosis and 
approximately 34 million are at an increased risk owing to low bone mass (National 
Osteoporosis Foundation 2007). Approximately 80% of those affected with osteopo-
rosis are women (National Osteoporosis Foundation 2007). In Canada, approximately 
1.4 million suffer from osteoporosis (Osteoporosis Canada 2007). In North America, 
20%–25% of women over the age of 50 have osteoporosis (Osteoporosis Canada 2007) 
and approximately 50% are estimated to have low bone mass (National Osteoporosis 
Foundation 2007).
For years, osteoporosis and CVD were thought to be independent chronic diseases 
that increased markedly with advancing age. However, increasing evidence now 
supports a direct association between these chronic conditions. Accordingly, in this Vascular Health and Risk Management 2006:2(4) 465–475
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Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
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circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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article we review the risk factors and patient proﬁ  les leading 
to both CVD and osteoporosis. Moreover, we review the 
mounting evidence that reveals an association between these 
diseases. We also discuss methods of reducing the risk for 
each chronic condition and the effects of these interventions 
on the subsequent risk for each disease. We discuss the 
differential rates with which osteoporosis and CVD affect 
men and women, and highlight how a holistic approach to 
these chronic conditions is warranted.
Traditional risk factors and patient 
proﬁ  les
Cardiovascular disease
Several traditional major independent risk factors for CVD 
have been identified including non-modifiable (family 
history, male sex, and advancing age) and modiﬁ  able risk 
factors. The major modiﬁ  able risk factors for CVD include 
elevated blood pressure, cigarette or tobacco smoking, physi-
cal inactivity, abnormal lipid lipoprotein proﬁ  les (eg, high 
total cholesterol, LDL cholesterol and triglycerides levels, 
and low levels of HDL cholesterol), unhealthy diets, exces-
sive alcohol use, obesity, and diabetes.
Recent research has also identiﬁ  ed several “emerging” 
or “novel” risk factors that are independent predictors of 
CVD and premature mortality. This includes factors such 
as vascular health (eg, arterial compliance, carotid intima 
media thickness, and pulse wave velocity), left ventricular 
mass, and a series of novel blood parameters (eg, lipoprotein 
(a), ﬁ  brinogen, C-reactive protein, and homocysteine). The 
measurement of  “emerging” risk factors in combination with 
a traditional lipid panel is thought to provide “information on 
risk over and above that supplied by established risk factors” 
(Heinrich and Assmann 1995).
The majority of CVD events are the result of atheroscle-
rosis (Grey et al 2003). The endothelium plays an important 
role in the process of atherosclerosis and thus has a signiﬁ  cant 
effect on the long-term risk for CVD (Leeson et al 1997). 
Endothelial dysfunction is thought to be an obligatory ﬁ  rst 
step in the process of atherosclerosis and has been observed 
in patients with coronary atherosclerosis (Sorensen et al 
1997) and individuals with risk factors for CVD (Celermajer 
et al 1994). Therefore, a healthy endothelium is essential 
for the protection against atherosclerosis (Anderson 2003). 
Endothelial dysfunction has been associated with multiple 
CVD risk factors and has also been reported to occur prior 
to the development of atherosclerosis (Celermajer et al 1992; 
Whitney et al 2004). It is important to note, that endothelial 
dysfunction has been observed in multiple chronic disease 
states including coronary artery disease, stroke, chronic heart 
failure, type 2 diabetes, hypertension, and obesity (Warburton 
et al 2006a).
Cardiovascular disease places a signiﬁ  cant burden upon 
health care systems worldwide. In Canada, CVD (includ-
ing heart disease and stroke) is the leading cause of death 
(accounting for over one-third of all deaths) disability, and 
hospitalization accounting for approximately 17% of the 
total health care costs (Wilson and Wielgosz 1999; Health 
Canada 1999; Katzmarzyk et al 2000). Cardiovascular 
diseases cost the Canadian economy $18 billion a year 
(Public Health Agency of Canada 2002). Fortunately, CVD 
is largely preventable.
In developed countries, many adults have one or more 
risk factor for CVD. For instance, 80% of Canadians have 
one or more risk factor for CVD (Health Canada 2005). As 
illustrated in Figure 1, the prevalence of modiﬁ  able risk 
factors for CVD in developed countries is alarming. Perhaps 
of more concern is the ﬁ  nding that many children and ado-
lescents have risk factors for CVD. For instance, in a recent 
study we revealed that 58% of children (10–11 yr) had at 
least one elevated CVD risk factor and approximately 8% 
of the children had four or more elevated CVD risk factors 
(McKay et al 2004). Clearly, effective prevention and treat-
ment interventions are required across the lifespan.
Osteoporosis
Several non-modiﬁ  able and modiﬁ  able risk factors have 
been identiﬁ  ed for osteoporosis. Non-modiﬁ  able risk factors 
include female sex (women are at greater risk), advancing 
age, personal history of a fracture after age 40, family history 
of osteoporosis, European or Asian ancestry, and dementia. 
Potentially modiﬁ  able factors include low BMI, calcium 
and vitamin D intake deﬁ  ciency, physical inactivity, certain 
medications (eg, excessive use of corticosteroids), estrogen 
deﬁ  ciency, current cigarette smoking, excessive alcohol con-
sumption, early menopause (before age 45), and prolonged 
pre-menopausal amenorrhea (>1 year) (Brown and Josse 
2002; Canadian Multicentre Osteoporosis Study 2006).
Osteoporosis is a major health burden affecting millions 
of people worldwide (particularly in developed countries) 
(World Health Organization 2003). In Canada approximately 
one in four women and one in eight men (over the age of 50) 
will have osteoporosis (Hanley and Josse 1996; Brown and 
Josse 2002). In developed countries, it has been estimated 
that 40%–54% of 50 yr old women will have an osteoporo-
sis-related fracture during their lifetime (Chrischilles et al 
1991; Melton et al 1992). The prevalence is higher amongst Vascular Health and Risk Management 2006:2(4) 465–475
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(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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older adults; however, osteoporosis can present itself at any 
age (Canadian Multicentre Osteoporosis Study 2006). The 
incidence of osteoporosis is positioned to increase markedly 
over the next few decades owing to the increasing numbers 
of older individuals worldwide (Brown and Josse 2002; 
Canadian Multicentre Osteoporosis Study 2006).
The burden osteoporosis places upon the individual, the 
family, and society as a whole is enormous. In Canada (1996 
data) hip fractures were the second leading cause of hospi-
tal admission for women aged 65 years or older (Statistics 
Canada 1999a). It has been estimated that without the creation 
of effective prevention and treatment strategies Canada will 
spend $1.9 billion per year to treat osteoporosis and related 
fractures (Osteoporosis Canada 2007).
Health-related quality of life is often markedly reduced 
in persons with osteoporosis. It has been estimated that 50% 
of women who sustain a hip fracture will become function-
ally dependent during activities of daily living, and 20% 
will require long term care (Chrischilles et al 1991; Brown 
and Josse 2002). Moreover, the incidence of premature 
mortality is 20% higher within a year of suffering a hip 
fracture (Chrischilles et al 1991; Brown and Josse 2002). 
Fortunately, osteoporotic fractures are preventable (Brown 
and Josse 2002).
The interrelationships between risk 
factors for cardiovascular disease 
and osteoporosis
In recent years, a growing body of literature (see Table 1) has 
revealed an association between CVD and osteoporosis. In 
particular, epidemiological evidence has shown a relationship 
between vascular calciﬁ  cation and bone loss (as reviewed 
in Table 1). For instance, bone mineral density has been 
inversely associated with coronary and/or aortic calciﬁ  ca-
tion (Uyama et al 1997; Barengolts et al 1998; Bagger et al 
2006), and directly associated with high-density lipoprotein 
cholesterol (HDL-C) (Yamaguchi et al 2002) (Table 1).
Clinical populations have also revealed a relationship 
between CVD and osteoporosis. For instance, accelerated bone 
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Figure 1 Prevalence of traditional risk factors for cardiovascular disease in Canadian society according to gender.
Note: High cholesterol was deﬁ  ned as a plasma cholesterol level above of 5.2 mmol·L-1; Diabetes was evaluated by self-report; Hypertension was deﬁ  ned as a blood 
pressure of ≥140/90 mmHg; Inactivity was deﬁ  ned as an usual daily leisure-time energy expenditure of <1.5 kcal·kg-1·day-1; Smoking was deﬁ  ned as daily tobacco smoking; 
Obesity was deﬁ  ned as a body mass index of >27; Alcohol was deﬁ  ned as alcohol use in excess of 9 and 14 drinks per week for women and men, respectively.
Source: Statistics Canada, National Population Health Survey, 1996/97 and the Heart and Stroke Foundation of Canada, The Changing Face of Heart Disease and Stroke in 
Canada 2000, October 1999 (Heart and Stroke Foundation of Canada 2000, Statistics Canada 1999b).Vascular Health and Risk Management 2006:2(4) 465–475
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Table 1 Relationship between vascular and bone health
Investigation Design Population Primary outcome 
measures
Key results
(Browner et al 
1991)
Prospective, 2.8y 9074 women, >65y BMD (SPA); cause of death 
(ICD-9 codes)
•   Each SD decrease in BMD of proxi-
mal radius resulted in a 70% increase 
stroke mortality.
•   Age-adjusted BMD revealed a weak 
association with CV mortality.
(Uyama et al 1997) Observational 30 women, 67–85y  BMD (DXA); carotid pla-
que score (ulltrasound)
•   Linear correlation with BMD and 
plaque score.
•   No association with L2-L4 BMD and 
plaque.
(Vogt et al 1997a) Observational 1292 women, mean 
age 71y
Blood ﬂ  ow-ankle/arm 
index; posterior tibial and 
brachial systolic BP; BMD 
(SPA and DXA)
•   >1SD change above mean annual index 
change resulted in reduced BMD at hip 
2 fold vs. smallest SD change.
•   A decrease of 2 SD in ankle/arm index 
was associated with a 3.7% decrease in 
hip BMD.
(Vogt et al 1997b) Observational 2051 women, >65y Aortic calciﬁ  cation (lateral 
radiographs); BMD (DXA)
•  No signiﬁ  cant association.
(Barengolts et al 
1998)
Observational  11 controls, 20 
osteopenic, 14 women 
with osteoporosis, 
mean age 65y
BMD (DXA), coronary 
calcium (QCT)
•   Osteoporosis group had a signiﬁ  cantly 
higher calcium score vs controls.
(von der Recke 
et al 1999)
Longitudinal obser-
vational
Recruited 1977–88, 
assessed 1994
309 women, mean 
age 50y
754 women, mean 
age 70y
Bone mass/BMC (SPA of 
forearm and lateral radiog-
raphy of spine)
Cause of death (ICD-9 
codes)
•   50y group: Each SD decrease in bone 
mass resulted in a 43% increase in all 
cause mortality and 2-fold increase in 
CV death.
•   70y group: Bone mass in lowest quartile 
was associated with a 2 fold increased 
risk of CV death vs highest quartile.
(Hak et al 2000) Longitudinal obser-
vational for >9y
Cross-sectional
236 women,
45–64y
720 women, mean 
age 63y
Aortic calciﬁ  cation (radio-
graphs), MCoA and RCoA
•   Progression of aortic calciﬁ  cation was 
associated with decreased MCoA 
(6.1%) and RCoA (8.9%).
•   No progression was associated with 
decreased MCoA (3.9%) and RCoA 
(6.9%).
•   Inverse, graded, association between 
extent of aortic calciﬁ  cation and 
MCoA/RCoA.
(Kado et al 2000) Longitudinal
observational,
5.7y
6046 women, mean 
age 76y
Rate of BMD loss; cause-
speciﬁ  c mortality
•   Each SD increase in rate of bone loss 
resulted in 1.3-fold increase in the risk 
of CHD death, 1.2-fold increase in the 
risk of atherosclerotic death and 1.6-
fold increase in the risk of death due 
to pulmonary causes.
(Kiel et al 2001) Longitudinal obser-
vational, 25–30y
346 women, 190 men, 
28–62y at start of 
study
Cortical bone mass 
(radiogrammetry); aortic 
calciﬁ  cation (radiographs)
•   Each percent decrease of MCoA was 
associated with 7.3% increase in aortic 
calciﬁ  cation index in women.
(Aoyagi et al 2001) Observational of a 
prospective cohort
524 Japanese Ameri-
can women,
43–80y
BMD of distal/proximal 
radius and calcaneus (SPA); 
aortic calciﬁ  cation (lateral 
and AP radiographs)
•   No signiﬁ  cant association between 
osteoporosis and aortic calciﬁ  cation.
(Yamaguchi et al 
2002)
Observational 214 women, 47–86y BMD, TC, LDL-C, HDL-C, 
TG
•   Inverse correlation with BMD and 
LDL-C.
•   Positive correlation with BMD and 
HDL-C.
(Continued)Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Investigation Design Population Primary outcome 
measures
Key results
•   Low TG levels associated with verte-
bral fracture.
(Tanko et al 2003) Observational 963 women, 60–85 yr Aortic calciﬁ  cation (graded 
on lateral lumbar radio-
graphs), and BMD (at the 
distal radius, lumbar spine, 
proximal femur)
•   Age, years since menopause, BMI, level 
of education, smoking history, and 
physical activity were signiﬁ  cant com-
mon risk factors for AC and hip BMD.
•   Aortic calciﬁ  cation was an independent 
predictor of hip BMD.
•   In a subgroup analysis, women with a his-
tory of intermittent claudication showed 
more severe aortic calciﬁ  cation, lower hip 
BMD, and a higher prevalence of CHD 
compared to age-matched controls.
(Kiechl et al 2004) Prospective, 
longitudinal (10 yr) 
population-based 
survey
N = 915, approxi-
mately 50% males and 
females (Mean Age 
approximately 59 yr)
Serum OPG, incident CVD, 
carotid atherosclerosis
•   Prevalence and severity of carotid 
atherosclerosis increased progressively 
with higher levels of OPG (even after 
controlling for sex and age).
•   OPG was a significant and indepen-
dent risk factor for 10-year incident 
cardiovascular disease and vascular 
mortality. 
(Schulz et al 2004) Observational 
Cross-sectional and
Longitudinal 
Cross-sectional: 2348 
postmenopausal 
women (50yrs and 
older)
Longitudinal: 228 post-
menopausal followed 
9 months to 8 yr later
Aortic calciﬁ  cation, BMD, 
fracture
•   Cross-sectional: Age-independent asso-
ciation between the degree of aortic 
calciﬁ  cation and bone density.
•   Aortic calciﬁ  cation was associated 
with a 4.8 and 2.9-fold increase in the 
risk for vertebral and hip fractures, 
respectively.
•   Bilateral hip fractures more common 
in those with calciﬁ  cation than those 
without.
•   Longitudinal: Graded relationship 
between bone loss and the progres-
sion of vascular calciﬁ  cation.
(Magnus and 
Broussard 2005)
Observational 5,050 women and 
men aged 50–79 yr 
BMD, MI (self-report), BMI, 
glucose, cholesterol, HDL, 
medications (self-report)
•   Participants who reported prior MI 
had signiﬁ  cantly higher odds of having 
low BMD (after adjusting for CVD and 
osteoporosis risk factors).
•   MI was signiﬁ  cantly associated with 
low BMD in men, but not women.
(Tanko et al 2005) Multicenter, random-
ized, double-blinded, 
placebo controlled
Followed for 4yrs
2576 women, 
mean age = 66.5 yr 
(assigned to placebo 
group)
Incidence of fatal or nonfa-
tal CV events, BMD (femo-
ral neck and lumbar spine), 
traditional risk factors for 
CVD (BMI, blood pressure, 
smoking habit, lipid proﬁ  le, 
and history or presence 
of hypertension, diabetes, 
hyperlipidemia, cardiovascu-
lar disease, and/or related 
major interventions) 
•   Osteoporotic women had a 3.9-fold 
increased risk for cardiovascular events 
than women with low bone mass.
•   Risk of cardiovascular events increased 
incrementally with the number and 
increasing severity of baseline vertebral 
fractures.
•   Composite cardiovascular risk was 
higher in women with osteoporosis 
and they were also more frequent 
users of cardiovascular medications.
•   The incidence of an acute cardiovas-
cular event during the follow up was 
higher in women with osteoporosis 
(evident for both coronary and stroke 
events).
(Continued)
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Investigation Design Population Primary outcome 
measures
Key results
•   Increased risk for cardiovascular 
events associated with osteoporosis 
could not be explained by common 
risk factors alone.
(Bagger et al 2006) Longitudinal obser-
vational, 7.5 yr
N = 2662 Postmeno-
pausal women, mean
age = 65 yr
Aortic calciﬁ  cation, BMD, 
vertebral fractures (X-ray),
hip fractures (self-report)
•   Advanced aortic calciﬁ  cation at base-
line was signiﬁ  cantly related to lower 
BMD and accelerated bone loss at the 
proximal femur.
•   The severity of aortic calciﬁ  cation 
was an independent predictor of hip 
fractures (OR = 2.3).
(Hermann-Arnhof 
et al 2006)
Observational 97 patients undergo-
ing elective coronary 
artery bypass surgery
OPG, cardiac troponin 
I, electrocardiography, 
homocysteine, C-reactive 
protein
•   Positive correlation between OPG 
before surgery and the number of 
diseased vessels.
•   Positive correlation between OPG 
before surgery and the number of 
bypasses.
•   Strong correlation between OPG 
before surgery and homocysteine
•   OPG level for four patients who 
experienced cardiac complications was 
elevated.
(Sinnott et al 2006) Observational 313 women (57 yr) 
and 167 men (55 yr)
Coronary calcium burden, 
BMD, self-report CHD risk 
factors, medical history
•   The degree of coronary calciﬁ  cation 
was inversely associated with BMD in 
postmenopausal women.   After control-
ling for age, this association was absent. 
(Jorgensen et al 
2006)
Prospective, longitu-
dinal, 6 yr 
2,733 women, aged 
55-74 yr
Carotid
Artery (echogenic) plaques, 
nonvertebral fractures
•   The age-adjusted relative risk of frac-
ture was signiﬁ  cantly higher in women 
with echogenic plagues (1.7 (95% 
conﬁ  dence interval 1.0–2.7).
(Bagger et al 2007) Observational 176 women, aged 
60–85 yr
Genotyped for epsilon 
(varepsilon) allelic variants 
of the ApoE gene, and mea-
sures of serum lipids (total 
cholesterol, triglycerides, 
HDL-C, LDL-C, apoA1, 
ApoB, Lp(a)), hip and spine 
BMD, aorta calciﬁ  cation, 
radiographic vertebral 
fracture and self-reported 
wrist and hip fractures, and 
cardiovascular events 
•   Presence of the ApoE varepsilon4 
allele was associated with a worsened 
serum lipid proﬁ  le, but had no asso-
ciation with spine/hip BMD or aortic 
calciﬁ  cation.
•   After adjusting for age, the risk of hip 
fractures but not wrist or vertebral 
fractures was increased in subjects 
with advanced vascular disease.
Abbreviations: AP, anterior posterior; BMC, bone mineral content; BMD, bone mineral density; BP, blood pressure; CHD, coronary heart disease; CV, cardiovascular; DXA, 
dual energy x-ray absorptiometry; HDL-C, high-density lipoprotein-cholesterol; ICD-9, International Classiﬁ  cation of Diseases (9th edition); L2-4, 2nd through 4th lumbar 
vertebrae; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; MCoA, metacarpal cortical area; PM, postmenopausal; QCT, quantitative 
computed tomography; RCoA, relative cortical area; SD, standard deviation; SPA, single photon absorptiometry; TC, total cholesterol; TG, triglycerides; OR, odds ratio; IMT, 
intimal medial thickening; OPG, osteoprotegerin; BMI, body mass index; MI, myocardial infarction.
Table (continued)
loss has been observed in diabetics (Schwartz et al 2005), a group 
that commonly exhibits marked vascular dysfunction (Romney 
and Lewanczuk 2001; McGavock et al 2004). Furthermore, 
in cases where vascular function is affected differentially on 
opposite sides of the body (ie, asymmetric vascular disease in 
the lower limbs), the side that has the greatest vascular dysfunc-
tion also displays the lowest bone mineral content (Laroche et al 
1994; Laroche et al 2003). Moreover, in elderly individuals who 
have experienced a fracture at the femoral neck, the blood vessels 
supplying the proximal femur are often atherosclerotic (Bocchi Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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et al 1985; Bocchi et al 1987). The rate of bone loss at the hip has 
also been shown to be greater in women who have the greatest 
reductions in blood ﬂ  ow (as assessed by the ankle/arm index) 
(Vogt et al 1997a).
The potential relationship between these chronic con-
ditions has important implications for the health of many 
individuals with (or at risk for) CVD and osteoporosis 
(Table 1) (Tanko et al 2005). For instance, investigations 
with post-menopausal women have observed that there is an 
increased risk of cardiovascular-related and stroke mortality 
for each standard deviation decrease in bone mass (Browner 
et al 1991; von der Recke et al 1999; Kado et al 2000). For 
instance, Kado et al (2000) revealed that for each standard 
deviation decrease in bone mass there was a 1.2- to 1.3-fold 
increased risk of dying from coronary artery disease or other 
forms of atherosclerosis. von der Recke et al (1999) reported 
that the lowest quartile of bone mass was associated with a 
2-fold increase in the risk for CVD-related death (vs. the 
highest quartile). Tanko et al (2005) revealed that osteopo-
rotic women had a 3.9-fold increased risk for cardiovascular 
events than women with low bone mass. This increased risk 
could not be explained by common risk factors alone. It is 
important to note however that studies have also shown no 
relationship between coronary calciﬁ  cation and osteoporosis 
after controlling for age (Sinnott et al 2006).
It remains to be determined the key mechanism(s) respon-
sible for the relationship between CVD and osteoporosis. As 
identiﬁ  ed above, both chronic conditions share similar modi-
ﬁ  able risk factors (such as physical inactivity, smoking, age, 
years since menopause, and excessive alcohol usage). How-
ever, researchers have shown a direct relationship between 
vascular disease and hip bone mineral density even after 
adjusting for a wide range of common risk factors (including 
age, years since menopause, BMI, level of education, current 
and previous smoking, and physical inactivity) (Tanko et al 
2003). Therefore, CVD and osteoporosis also may be linked by 
common pathophysiological mechanisms (Tanko et al 2003). 
The available epidemiological evidence does not allow for the 
establishment of a causal link between CVD and osteoporosis. 
However, there are plausible biological pathways whereby 
diminished cardiovascular health can inﬂ  uence bone health 
and vice versa (Whitney et al 2004). Several excellent reviews 
have been created recently on these topics (Doherty et al 2003; 
Hamerman 2005; Rajzbaum and Bezie 2006).
Potential mechanisms
There is evidence that vascular calcification has several 
common features to bone formation at both the cellular and 
molecular level. As stated by Doherty et al (2003) “calciﬁ  ed 
atherosclerotic arteries can contain tissue that is histomor-
phologically indistinguishable from bone.” Vascular calcium 
deposition is now thought to be an active, complex, and regu-
lated process similar to new bone formation (or remodeling) 
that is not merely a consequence of aging (Doherty et al 2003; 
Rubin and Silverberg 2004). Importantly, calcifying vascular 
cells appear to have the ability to experience osteoblast dif-
ferentiation (Rubin and Silverberg 2004). Moreover, it has 
been hypothesized that there are arterial cells that can differ-
entiate into mineral resorbing cells (ie, osteoclast-like cells) 
(Doherty et al 2002). These cells are thought to be derived 
from hematopoietic precursors of the mononuclear phagocytic 
lineage (Doherty et al 2002). Doherty et al (2002) postulated 
that osteoclast-like cells may play a role in the delicate balance 
of mineral deposition and resorption within the arterial wall 
(similar to that seen in bone). These authors also considered 
arterial mineral deposition “as a localized failure of protective 
mechanisms that actively oppose mineral deposition within 
the disordered metabolic milieu of developing atherosclerotic 
plaque.” This supports a growing body of research that indi-
cates that arterial calciﬁ  cation involves arterial osteoblast- and 
osteoclast-like cells (Doherty et al 2003).
Both the artery wall and the osteon of cortical bone have 
a common endothelium lined lumen. Cancellous bone is 
also highly vascular. Moreover, calciﬁ  ed plaque has been 
shown to have numerous cellular and molecular elements that 
participate in bone formation including (but not exclusive 
to) bone morphogenetic protein-2, collagen 1, osteonectin, 
osteopontin, matrix Gla proteins, osteocalcin and osteopro-
tegerin (Doherty et al 2003; Whitney et al 2004; Hamerman 
2005).
Several biological mechanisms (based primarily on animal 
models) have been proposed to explain the link between CVD 
and osteoporosis (see reviews of Doherty et al 2003; Hamerman 
2005; and Rajzbaum and Bezie 2006). Chronic inﬂ  ammation 
is known to play a role in the development of both chronic 
conditions. For instance, proinﬂ  ammatory cytokines (including 
interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)) 
have been associated with vascular disease (Blake and Ridker 
2001) as well as increasing bone resorption (Cohen-Solal et al 
1993). Also, both bone and the vasculature are affected by sex 
steroids (Stevenson 2004; Rossouw 2005). For example, estro-
gens play a role in CVD and osteoporosis via their effects on 
cytokines (including IL-6, osteoprotegerin (as discussed later), 
and TNF-α) (Baldini et al 2005).
As outlined above, vascular calciﬁ  cations and bone 
have several similarities (Hamerman 2005; Rajzbaum and Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Bezie 2006). Several compounds found within arterial 
wall calciﬁ  cations have been implicated in the association 
between bone loss and CVD. For instance, osteoprotegerin 
(an important regulator of osteoclastgenesis) has recently 
received considerable attention. Osteoprotegerin is a member 
of the TNF receptor superfamily that serves as a bone resorp-
tion inhibitor by blocking the RANK-L/RANK interaction 
(Kiechl et al 2004; Rajzbaum and Bezie 2006). Animal and 
human studies have reported conﬂ  icting ﬁ  ndings regarding 
the role of osteoprotegerin in CVD and osteoporosis. Mice 
that do not have the osteoprotegerin gene exhibit vascular 
calciﬁ  cations and osteoporosis (Bucay et al 1998). The 
intravenous administration of osteoprotegerin into mice 
deﬁ  cient in osteoprotegerin reversed the osteoporosis, but 
it did not correct the arterial calciﬁ  cation. Whereas, the 
transgenic osteoprotegerin gene delivered during gestation 
prevented the formation of arterial calciﬁ  cation in osteopro-
tegerin deﬁ  cient mice (Min et al 2000). In humans, a high 
level of osteoprotegerin has paradoxically been shown to 
be an independent risk factor for the progression of athero-
sclerosis and the development of CVD (Browner et al 2001; 
Kiechl et al 2004). Similarly, high levels of osteoprotegerin 
were observed in post-menopausal women with osteoporosis 
(Yano et al 1999). Based on animal literature, it would be 
anticipated that high osteoprotegerin levels would be associ-
ated with high bone mineral density (Hamerman 2005). Yano 
et al (1999) postulated that the high osteoprotegerin levels (in 
osteoporotic post-menopausal women) may reﬂ  ect a compen-
satory response to enhanced osteoclastic bone resorption.
Serum lipids (a well-established risk factor for athero-
genesis) have been proposed as one common mechanism for 
CVD and osteoporosis. It has been postulated that oxidized 
lipid accumulation in the subendothelial space of arteries 
promotes arterial calciﬁ  cation and inhibits bone mineral 
formation (Parhami et al 2000). Lipids have been shown to 
have effects on osteoblasts (Parhami et al 1997, 2000, 2002) 
and osteoclasts (Tintut et al 2004). For instance, the same 
oxidized lipids that bring about osteoblast differentiation 
in calcifying vascular cells inhibit osteoblast differentia-
tion in bone cells of mice (Parhami et al 1997). Moreover, 
in atherogenic susceptible and resistant mice exposed to a 
high fat or normal diet, a 35% decrease in both bone min-
eral content (BMC) and osteocalcin expression was found 
in the fat fed, atherogenic susceptible strain (Parhami et al 
1999; Parhami et al 2001). Animal work also revealed that 
hyperlipidemia may lead to osteoporosis via an increase in 
osteoclastic bone resorption (Tintut et al 2004). Prolonged 
treatment with high-density lipoprotein has also been shown 
to inhibit the osteogenic activity of calcifying vascular cells. 
Moreover, HDL inhibited the osteogenic activity induced by 
inﬂ  ammatory cytokines (Parhami et al 2002).
Epidemiological evidence in humans examining the role 
of lipids in the relationship between CVD and osteoporosis 
remains controversial. For instance, there is evidence that 
hyperlipidemia (eg, elevated low-density lipoprotein) is 
associated with reduced bone mineral density (Yamaguchi 
et al 2002). However, abnormal lipid lipoprotein levels have 
also been shown to be associated with increased bone min-
eral density in humans (Adami et al 2004). Whereas, others 
have found no independent relationship between lipids and 
bone mineral density (Bagger et al 2007). For example, 
Bagger et al (2007) recently reported that there were no 
independent associations with lipid lipoprotein proﬁ  le and 
bone mineral density of the hip or spine. Importantly, the 
authors also revealed that the severity of aorta calciﬁ  cation 
was independently associated with hip bone mineral density 
(with no contribution of lipids). The authors stated that these 
discrepancies provide evidence that the obstructive vascular 
disease (rather than lipid lipoproteins per se) facilitates the 
bone loss. The authors also postulated that lipids may act 
indirectly via the promotion of atherosclerosis which in 
turn can affect local bone metabolism. This effect is thought 
to be particularly evident at skeletal sites with end-arterial 
blood supply (Bagger et al 2007). This evidence supports 
the argument that a decrease in peripheral blood ﬂ  ow and 
supply could suppress bone cell function (Rubin and Sil-
verberg 2004).
Endothelial function appears to be important for both 
vascular and bone health. The vascular endothelium provides 
a macromolecular barrier with multiple functions including: 
1) anti-inﬂ  ammation and pro-inﬂ  ammation, 2) vasodilatation 
and vasoconstriction, 3) anti-thrombosis and pro-thrombosis, 
4) anti-oxidation and pro-oxidation, and 5) growth inhibition 
and growth promotion (Whitney et al 2004). When the integ-
rity of the endothelium is disrupted, as with oxidized LDL-C, 
an imbalance in these roles occurs resulting in endothelial 
dysfunction. Endothelial dysfunction is thought to be an 
obligatory ﬁ  rst step in the process of atherosclerosis. Owing 
to the intimate contact with endothelial cells, the health of 
the endothelium appears to also be of great signiﬁ  cance for 
bone health.
A healthy vascular tone is maintained by the continual 
release of low levels of nitric oxide (NO). NO is generated 
from L-arginine by NO synthase isoenzymes. Three NO 
synthase isoforms have been identiﬁ  ed including a neuronal 
form (nNOS), an endothelial form (eNOS), and an inducible Vascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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form (iNOS). Recently, it has become apparent that NO is 
involved in the process of bone metabolism and as such the 
inﬂ  uence of NO on bone health has been the focus of several 
investigations. In bone, it has been established that nNOS is 
rarely expressed, while both eNOS and iNOS are expressed 
(Fox and Chow 1998). However, both the eNOS and nNOS 
isoforms affect bone differently. For instance, the eNOS 
isoform is expressed constitutively and is predominant in 
the osteoblast lineage (Fox and Chow 1998). Inﬂ  ammation 
is associated with iNOS activity in osteoblast and osteoclast 
cells (Fox and Chow 1998; Armour et al 1999; Armour et al 
2001b). For instance, Armour et al (2001b) revealed that the 
activation of the iNOS pathway contributes to inﬂ  amma-
tion-mediated osteoporosis via suppressed bone formation 
and osteoblast apoptosis. Osteoclasts have also shown low 
levels of eNOS and iNOS (Fox and Chow 1998). eNOS 
negative (knock-out) mice have demonstrated reduced bone 
volume, bone formation rates, BMD, and osteoblast num-
bers (Aguirre et al 2001; Armour et al 2001a; Samuels et al 
2001). eNOS knock-out mice have also revealed a blunted 
response to exogenous estrogen, supporting the important 
role of eNOS in mediating the stimulatory action of estrogen 
on bone formation (Armour et al 2001a). Moreover, cells of 
osteoblast phenotype challenged with pulsatile ﬂ  uid ﬂ  ow 
(as seen with exercise) have demonstrated increased eNOS 
production (Klein-Nulend et al 1998). Researchers have also 
shown that L-arginine administration prevented bone loss 
and bone collagen breakdown in cyclosporin A-treated rats 
(Fiore et al 2000).
These ﬁ  ndings (from animal and cell culture models) 
indicate that NO may contribute to the osteogenic pathway. 
However, exactly how eNOS and iNOS contribute to bone 
health remains to be determined, especially in humans. 
Prospective human investigations have evaluated NO and 
bone (Jamal et al 1998; Nabhan 2006). For instance, Jamal 
et al (1998) revealed that intermittent nitrate use increased 
hip and heel BMD compared to non-users. However, there 
was no difference in fracture free survival between groups. 
A recent randomized controlled trial (Nabhan 2006) revealed 
that isosorbide mononitrate (a NO donor) was effective in 
reducing a marker of bone resorption (urine N-telopeptide) and 
increasing a marker of bone formation (alkaline phosphatase) 
in post-menopausal women. The authors postulated that a NO 
donor may be effective in the prevention of post-menopausal 
osteoporosis. Additional research is required to clearly identify 
the roles that the speciﬁ  c NO isoforms have on bone health.
Other factors involved in arterial wall calciﬁ  cation have 
also been implicated in the relationship between CVD and 
osteoporosis. Potential factors include (but are not exclusive 
to) osteopontin, matrix Gla-proteins and osteocalcin, and 
leptin. It is recommended that interested readers consult 
reviews on this topic (Doherty et al 2003; Hamerman 2005; 
Rajzbaum and Bezie 2006) for further information regarding 
the varied potential mechanisms explaining the relationship 
between CVD and osteoporosis.
Based on the above literature it is apparent that multiple 
pathophysiological mechanisms can be responsible for the 
observed relationship between CVD and osteoporosis. It is 
however important to note that many of the above ﬁ  ndings 
provide evidence that vascular dysfunction plays a key role 
in the association between CVD and osteoporosis. Thus, 
impaired blood ﬂ  ow and a diseased vascular system may 
have negative effects on bone health, or diseased bone may 
impair vascular health (Whitney et al 2004).
Differences between men, pre-
and postmenopausal women
It is important to discuss the differences between men and 
women across the lifespan with respect to the risk for and 
prevalence of CVD and osteoporosis. Often CVD is thought 
to be a disease of primary concern for men and osteoporosis 
of primary concern for women owing to the differential 
prevalence rates for each condition amongst sexes. However, 
these statements must be tempered greatly owing to the 
unique sex-based differences in each condition.
With respect to CVD, men are more prone to athero-
sclerosis (approximately 3–4 fold greater) than women 
(Eaker et al 1993, American Heart Association 2006). 
With aging, this ratio declines to approximately 2 between 
the ages of 65–69, and to 1 by the age of 85 (Eaker et al 
1993). The incidence of CVD increases markedly in 
women after menopause (Witteman et al 1989). It has 
been estimated that the coronary heart disease rates 
increase 2–3 fold after menopause in women (increasing 
with aging) (American Heart Association 2006). Recent 
American data indicates that the prevalence of coronary 
heart disease in women 75 years or older was 10.3% in 
comparison to 1.6% between the ages of 45–54 (American 
Heart Association 2006).
The majority of sudden cardiac deaths occur in men 
(approximately 3–4 fold greater incidence); however, this 
inequality is also reduced with advancing age (American 
Heart Association 2006). Men have been shown to have 
a higher blood pressure than women until approximately 
age 45; thereafter, women have a higher blood pres-
sure (American Heart Association 2006). This sex-based Vascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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difference appears to be particularly pronounced in the 
elderly. For instance, in the United States the prevalence of 
hypertension is approximately 34% for both men and women 
aged 45–64. However, in the 75%+ cohort women have an 
increased prevalence of high blood pressure than men (83 
vs 69%, respectively) (American Heart Association 2006). 
Although men (under the age of 75) have greater prevalence 
of coronary heart disease, women have a greater prevalence 
of CVD events due to heart failure (American Heart Asso-
ciation 2006).
The death rates associated with a myocardial infarction 
appear to be higher in women than men (Greenland et al 1991; 
Gottlieb et al 2000 ). For instance, in the United States, 25% 
of men and 38% of women die within one year after have an 
initial myocardial infarction (American Heart Association 
2006). This may be in part due to the fact that women are 
often older when they have a myocardial infarction. More 
American women (64%) than men (50%) who die suddenly 
due to CVD had no previous symptoms (American Heart 
Association 2006).
There is an increased incidence of osteoporosis in 
women (approximately 80%) (National Osteoporosis 
Foundation 2007). The incidence of osteoporosis increases 
markedly after the age of menopause with approximately 
1 in 4 women over the age of 50 exhibiting osteoporosis 
(Osteoporosis Canada 2007). This has led to a primary focus 
on elderly women in research within the ﬁ  eld; however, 
approximately 30% of hip fractures occur in men. Men 
also have a higher risk of dying after a fracture (Center 
et al 1999). It has been estimated that the mortality rate in 
the ﬁ  rst year after a fracture in men is twice that of women 
(Wright 2006).
Risk management of cardiovascular 
disease and osteoporosis
With the projected progressive increase in life expectancy 
it is clear that the incidence of both CVD and osteoporo-
sis will increase for both males and females. Therefore, 
effective preventive interventions are required to offset 
the inevitable burden these chronic conditions will place 
upon society. It is also important to note, that with the 
global increase in life expectancy a major challenge 
for public health care systems will be the enhancement 
of overall quality of life, and not solely the prevention 
of chronic disease. Life expectancy does not take into 
account the years a person may live in a dependent or 
diseased state. Since overall quality of life is of utmost 
importance (especially as one ages) recent health agencies 
(such as the World Health Organization) have adopted 
new criteria to determine the number of years a person 
might live in a healthy state. For instance, the World 
Health Organization has recently introduced the Health-
Adjusted Life Expectancy (HALE) scale that takes into 
account the anticipated years of ill-health to provide an 
estimate of years of healthy living (Figure 2).
Health-related quality of life includes physiological, 
functional, emotional and spiritual well-being. We have 
discussed previously the physiological determinants of 
chronic disease. However, a holistic approach to health care 
should also include the evaluation of the other determinants 
of health-related quality of life. For instance, emotional and 
spiritual well-being are key factors in maintaining a high 
quality of life across the lifespan (Warburton et al 2001a, 
2001b). Moreover, the maintenance of functional capacity 
is fundamental to healthy aging (Warburton et al 2001a, 
2001b). Functional independence, especially as one ages, is 
related largely to one’s ability to perform activities of daily 
living. In fact, the capacity to carry out activities of daily 
living is thought to be of greater concern to the elderly than 
chronic disease (Ensrud et al 1994; Warburton et al 2001a, 
2001b, 2006a). Therefore, preventative strategies should be 
developed that not only speciﬁ  cally target individual risk 
factors for chronic disease, but also address the emotional, 
physical and social well-being of the individual (Warburton 
et al 2001a, 2001b; Palacios et al 2005).
It is essential to stress that preventative strategies for 
both CVD and osteoporosis should not focus solely on 
the elderly at the expense of younger generations (Center 
et al 1999). It is clear that CVD starts in childhood and 
progresses with advancing age. It has been estimated 
that approximately one half of North American children 
exhibit one or more risk factor for CVD, with up to a 
third exhibiting at least one risk factor by the time they 
enter elementary school (Freedman et al 1999). In fact, 
many children and adolescents exhibit multiple risk fac-
tors for CVD (Troiano et al 1995; Berenson et al 1998; 
McGill et al 2000). As discussed previously, we have 
recently shown that 8% of elementary children had four 
or more CVD risk factors (McKay et al 2004). This is 
of concern owing to the fact that the severity of under-
lying cardiovascular disease is greater with increasing 
numbers of CVD risk factors (Berenson et al 1998) and 
these children may be more likely to develop CVD in 
adulthood (Reid et al 1999). Moreover, childhood and 
adolescence are important periods for the development 
of bone health. In fact, approximately 90% of adult bone Vascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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mass is accrued by the end of adolescence (McKay et al 
2005). Effective interventions (in particular interven-
tions involving mechanical loading) can have marked 
effects upon bone metabolism and health during the 
growing years (McKay et al 2005). For instance, exercise 
interventions have been shown to have a greater effect 
when started in premenarche compared to postmenarche 
(Kannus et al 1995). It appears that benefits derived 
from interventions that optimize peak bone mass (such 
as weight-bearing exercise) may extend into adulthood 
(Khan et al 2000). Therefore, preventative interventions 
must be devised that meet the needs of individuals from 
across the lifespan.
We feel that a preventative model across the lifespan is 
required to effectively address the high prevalence of CVD 
and osteoporosis, and to improve overall quality of life. 
Given the interrelationships between multiple chronic disease 
states a holistic approach to medicine should be advocated. 
In short, rather than focusing on the prevention and treatment 
of single disease states we should consider the treatment 
of the whole patient. Physical activity interventions have 
shown this strategy will hold great potential for addressing 
concurrently multiple chronic diseases, while improving 
overall quality of life.
Does minimizing the risk in one 
disease predispose an individual
to risk in the other?
As discussed above, effective interventions can concur-
rently target multiple modiﬁ  able risk factors for both CVD 
and osteoporosis. For instance, the cessation of smoking 
and an increase in weight-bearing physical activity would 
each have a beneﬁ  cial effect on both chronic conditions. 
However, clinicians must be aware that there is the poten-
tial for the reduction of risk in one disease to predispose 
the individual to an increased risk for the other condition. 
Perhaps the best example of this is weight reduction for 
the treatment of CVD. This is owing to the fact that a low 
BMI is an independent predictor of the risk for osteoporosis 
(De Laet et al 2005). For instance, De Laet et al (2005) 
revealed that a BMI of 20 kg/m2 was associated with a 
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JPN SWI AUS SWE FRA CAN ITA SPN NOR NZL UK USA SL
0
20
40
60
80
100
LEX
HALE
L
i
f
e
 
E
x
p
e
c
t
a
n
c
y
 
(
y
r
)
Figure 2 Life expectancy and health-adjusted life expectancy in representative nations.
Abbreviations: LEX, Life Expectancy; HALE, Health-Adjusted Life Expectancy; JPN, Japan; SWI, Switzerland; AUS, Australia; SWE, Sweden; FRA, France; CAN, Canada; ITA, 
Italy; SPN, Spain; NOR, Norway; NZL, New Zealand; UK, United Kingdom; USA, United States of America; SL, Sierra Leone.
The Health-Adjusted Life Expectancy (HALE) Takes into account the years of ill-health, weighted according to severity, and subtracted from the anticipated life expectancy 
to provide the equivalent years of healthy life.
Source: World Health Organization, World Health Report 2001. http://www3.who.int/whosis/hale/hale.cfm?path=whosis,hale&language=english (World Health Organiza-
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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2-fold increase in the risk for hip fracture in comparison 
to a BMI of 25 kg/m2. The risk for hip fracture however 
does not appear to be linear across BMI levels, as a BMI 
of 30 kg/m2 only conferred a 17% reduction in hip fracture 
risk in comparison to a BMI of 25 kg/m2. It appears that 
weight loss is also associated with an increased risk for 
osteoporosis (Ensrud et al 2005; Macdonald et al 2005). 
Macdonald et al (2005) recommended that postmenopausal 
women (who are not taking hormone-replacement therapy) 
should be informed that low body weight or losing weight 
may worsen the degree of bone loss. Therefore, although 
losing weight confers health beneﬁ  ts for CVD, it may be 
counterproductive for osteoporosis. However, the level 
of weight loss often achieved in patients with CVD after 
lifestyle and/or pharmacological interventions is often not 
excessive and as such may confer limited additional risk for 
the development of osteoporosis. In fact, given the appar-
ent relationship between CVD and osteoporosis it is likely 
that the changes in vascular health would be of great health 
beneﬁ  t to the individual patient. It is important to note, that 
there are interventions (such as physical activity) that can 
meet the needs of both chronic conditions without markedly 
compromising the cardiovascular or skeletal health. This is 
particularly salient given the beneﬁ  cial exercise-associated 
changes in bone and vascular health.
Hormone replacement therapy
Postmenopausal hormone therapy has been widely advo-
cated for the prevention of osteoporosis and the treatment 
of postmenopausal symptoms (Brown and Josse 2002). It 
was also anticipated that estrogen replacement therapy or 
combined estrogen-progestin therapy (hormone replace-
ment therapy) would lower CVD risk (Alexandersen et al 
2006). In fact, during the early 1990s hormone therapy was 
widely promoted as an effective primary and secondary 
preventive strategy against CVD (Rossouw 2005). This 
was based largely on epidemiological (observational) 
studies that demonstrated a beneﬁ  cial effect of hormone 
replacement therapy on risk factors and outcomes for CVD 
(Stampfer et al 1991; Grodstein et al 1996). However, the 
results of hormone replacement therapy clinical trials have 
had conﬂ  icting effects with respect to the risk for CVD. For 
instance, the Heart and Estrogen/Progestin Replacement 
Studies (HERS I and II) (Hulley et al 1998; Grady et al 
2002) and the Women’s Estrogen for Stroke Trial (WEST) 
(Viscoli et al 2001) did not show a reduction in the incidence 
of CVD. Moreover, the Women’s Health Initiative (WHI) 
terminated early the trial of estrogen plus progestin owing 
to increased risks of breast cancer and cardiovascular events 
(Rossouw et al 2002). Recently, Alexandersen et al (2006) 
revealed that 2–3 years of hormone replacement therapy 
does not increase all-cause mortality and may lead to car-
diovascular health beneﬁ  ts (including decreased severity of 
aortic calciﬁ  cation). Owing to the discrepancies in the ﬁ  eld, 
it is apparent that hormone replacement therapy should be 
used cautiously considering the risk beneﬁ  t ratio for each 
individual patient.
Priority: Cardiovascular disease 
versus osteoporosis
Physicians and health care professionals are often met with 
the challenge of assessing and managing the risk of indi-
viduals with varied medical conditions (such as multiple 
chronic diseases). In terms of screening and risk management 
osteoporosis is often considered to be of lower priority than 
cardiovascular disease.
While the incidence of CVD-related mortality and mor-
bidity is shown to be greater than that for osteoporosis, the 
importance of preventing and treating osteoporosis cannot be 
discounted. As discussed previously, osteoporosis affects a 
signiﬁ  cant proportion of society (in particular elderly women). 
Further, as the population ages, these numbers are expected 
to increase substantially (Tucci 2006). The economic and 
societal implications of osteoporosis are considerable owing 
to the signiﬁ  cant morbidity, mortality, and health care costs 
associated with osteoporotic fractures (Sasser et al 2005; 
Mauck and Clarke 2006). According to Sasser et al (2005), 
in the United States alone, the average annual direct costs 
of osteoporosis per patient is $6,259 while the indirect cost 
associated with the disease is $4,039 demonstrating a signiﬁ  -
cant ﬁ  nancial burden. Therefore, overcoming the challenge 
of providing optimal health care while managing the costs 
associated with treatment is of great concern (especially as 
the population ages) (Mauck and Clarke 2006; Tucci 2006). 
Tucci (2006) suggests that in order to control costs, post-frac-
ture care and identiﬁ  cation of individuals with an increased 
risk of fracture may enable cost-effective management and 
treatment of osteoporosis. It is therefore necessary to ensure 
effective preventative measures and treatment protocols in 
order to reduce the number of individuals at risk of develop-
ing osteoporosis and experiencing an osteoporosis-related 
fracture (Tucci 2006).
Fortunately, exercise interventions can help address 
both CVD and osteoporosis concurrently, thereby limiting 
the need for clinicians to prioritize between conditions. 
In fact, it is likely that primary and secondary prevention Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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through healthy lifestyle interventions may serve to 
decrease the physical, social, emotional and spiritual 
impairments to the individual as well as decrease the direct 
and indirect medical costs associated with the treatment 
of both conditions.
Physical activity and its role in the 
prevention of CVD and osteoporosis
Physical inactivity is a major risk factor for both osteoporo-
sis and CVD (Warburton et al 2006a, 2006b). There is also 
extensive literature indicating that physical activity is an 
effective primary and secondary preventive strategy against 
CVD, osteoporosis, and multiple other chronic diseases 
(including obesity, stroke, hypertension, type 2 diabetes, 
colon cancer, breast cancer, and several psychological dis-
orders) (Warburton et al 2006a).
Being ﬁ  t or physically active has been shown to lead to a 
30%–50% reduction in the risk of death from any cause and 
from CVD (Warburton et al 2006a). Low maximal aerobic 
ﬁ  tness is as important a risk factor for premature mortality 
as is overweight and obesity (Blair and Brodney 1999). 
Several mechanisms may explain the reduced premature 
mortality rates and incidence of CVD in individuals who 
are habitually active (Warburton et al 2006a, 2006b). For 
instance, regular aerobic exercise has been shown to improve 
body composition (via reduced abdominal adiposity and/or 
improved weight control) ( Tremblay et al 1990; Seidell et 
al 1991; Slattery et al 1992; Maiorana et al 2003), enhance 
lipid lipoprotein proﬁ  les (including increased HDL-choles-
terol, reduced triglycerides, and decreased LDL-cholesterol) 
(Taimela et al 1994; Halle et al 1996; Berg et al 1997), 
improve glucose homeostasis (Wallberg-Henriksson et al 
1998; Kelley and Goodpaster 1999), decrease blood pressure 
(American College of Sports Medicine 1993; Warburton 
et al 2006a), reduce systemic inﬂ  ammation (Adamopoulos 
et al 2001), enhance cardiac function (Warburton et al 1999, 
2004a, 2004b), and improve endothelial function (Gokce et 
al 2002; Hambrecht et al 2003; Kobayashi et al 2003).
Particularly relevant to this discussion is the exercise-
mediated changes in vascular health and endothelial func-
tion. Several studies have evaluated the effects of habitual 
exercise on endothelial function in elderly and patient 
populations. Cross-sectional investigations have revealed 
that active older adults have improved vascular health in 
comparison to sedentary individuals (Taddei et al 2000; 
McKechnie et al 2001; Galetta et al 2006a). Moreover, 
habitual physical activity appears to attenuate the age-
associated decline in endothelial function (Taddei et al 
2000; Galetta et al 2006a, 2006b). Research trials have also 
revealed the ability of exercise interventions to improve 
vascular health and endothelial function in asymptomatic 
and symptomatic populations (Hambrecht et al 1998, 2000, 
2003; Gokce et al 2002; Kobayashi et al 2003) (with the 
beneﬁ  cial adaptations being particularly apparent in clinical 
populations (Green et al 2004)).
A direct relationship exists between lifetime physical 
activity and bone health. In particular, weight-bearing exer-
cise appears to have a great effect on bone mineral density 
(Warburton et al 2001a, 2001b, 2006a). For instance, adults 
performing repetitive, high-intensity, weight-bearing exercise 
consistently have greater BMD than sedentary individuals 
(Bassey and Ramsdale 1994; Heinonen et al 1995; Lohman 
et al 1995; Warburton et al 2001a, 2001b). Prospective stud-
ies in post-menopausal women using weight bearing activ-
ity have often reported an increase or maintenance of total 
body, hip, and lumbar spine bone mineral density (Hatori 
et al 1993; Welsh and Rutherford 1996; Kohrt et al 1997). 
In fact, resistance training often results in site-speciﬁ  c and 
load-dependent improvements in BMD (Smidt et al 1992; 
Kerr et al 1996; Kohrt et al 1997; Warburton et al 2001a, 
2001b). A meta-analysis of randomized controlled trials 
reported that exercise training interventions result in the 
prevention or reversal of approximately 1% of bone loss per 
year in the lumbar spine and femoral neck in both pre- and 
post-menopausal women (Wolff et al 1999). Moreover, exer-
cise training has been shown to reduce the risk and number 
of falls (Tinetti et al 1994; Wolf et al 1996; Shaw and Snow 
1998; Carter et al 2001a, 2001b; Liu-Ambrose et al 2004a) 
and fractures (Stevens et al 1997; Joakimsen et al 1998; 
Gregg et al 2000; Kujala et al 2000). Preliminary evidence 
also indicates that routine physical activity is effective in 
improving bone density in older women with low bone 
mineral density (Liu-Ambrose et al 2004b).
It is clear that regular physical activity prolongs one’s 
lifespan (Lee et al 1997), but it also delays greatly the onset 
of chronic disease and/or disability. Therefore, physical 
activity is an effective means to increase the number of years 
that a person lives in a healthy state, thereby minimizing the 
years spent in a dependent state. If disability does occur it is 
generally for a short period of time at the end of life (Powell 
and Blair 1994). This is particularly important with the ever-
increasing aging population.
Summary
It is clear that both CVD and osteoporosis are major health 
burdens affecting millions of people globally. A growing Vascular Health and Risk Management 2006:2(4) 465–475
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(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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body of research supports a direct association between CVD 
and osteoporosis providing an explanation for why (in part) 
individuals often exhibit both chronic conditions. There 
are numerous factors that may account for this relationship 
including risk factors that are common to both debilitating 
chronic conditions, and varied pathophysiological mecha-
nisms. Both chronic conditions share similar modiﬁ  able 
risk factors (including physical inactivity) and such effec-
tive treatment strategies can be developed to address both 
diseases.
There appear to be distinct differences between (and 
within) sexes across the lifespan with respect to each 
chronic condition that need to be considered when treating 
the individual patient. It is important to have an under-
standing of the effects of varied primary and secondary 
preventative strategies on multiple chronic conditions. 
Preventative strategies should not only target individual 
risk factors for chronic disease, but also address the overall 
health-related quality of life of the individual. We advocate 
a holistic approach to the prevention and treatment of these 
chronic debilitating diseases; an approach that considers 
the social, emotional, spiritual and physical well-being of 
the individual.
When designing an intervention (such as a physical 
activity intervention) to address both chronic conditions, 
clinicians must be able to balance the risk of each condition. 
Clinicians must be aware that there is a potential for the risk 
reduction in one disease to predispose the individual to an 
increased risk for the other condition. With this knowledge, 
clinicians will be able to develop effective interventions that 
attenuate the risk while addressing the speciﬁ  c limitations of 
each chronic condition.
Although CVD takes a higher toll on society in terms 
of premature mortality, morbidity rates, and health care 
costs, the importance of the prevention/treatment of 
osteoporosis (particularly in elderly women) can not be 
overlooked. Habitual physical activity is an effective pri-
mary and secondary preventative strategy for both chronic 
conditions across the lifespan. Training-induced adapta-
tions in endothelial function appear to be particularly 
important for the concurrent reductions in the risk of 
CVD and osteoporosis.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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